Saturday 17 October 2026
Export PMCB’s income statement to Excel — free account
Nuvilex Inc.
PMCB Healthcare Biotechnology
In the quarter to July 2026, EPS grew 56.1% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.34
0.02
−5.56%
Follow PMCB
| Older periods | Oct '25 | Jan '26 | Apr '26 | Jul '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
14.60 | 12.33 | 45.28 | 40.29 |
Net Debt/EBITDA |
11.34 | 9.70 | 14.77 | 30.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.12 | 0.51 | 0.29 | 0.14 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(0.14) | (0.08) | (0.17) | (0.07) | |
Cash per Share |
2.30 | 2.22 | 4.43 | 2.84 | |
Shareholders Equity per Share |
5.18 | 4.11 | 3.97 | 2.56 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.18 | 4.11 | 3.97 | 2.56 | |
Free Cash Flow |
(0.98) | (0.79) | (1.39) | (0.78) | |
Working Capital |
21.45 | 19.02 | 36.59 | 30.21 | |
Net Current Asset Value |
2.28 | 2.94 | 23.96 | 21.77 | |
| Other line items | |||||
Quick Ratio |
13.06 | 12.24 | 45.16 | 40.25 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.14) | (0.08) | (0.17) | (0.07) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
— | — | — | 2.06 | |
Average Payables |
0.68 | 0.84 | 0.34 | 0.43 | |
Average Assets |
55.54 | 49.85 | 50.96 | 40.91 | |
Average Common Equity |
39.34 | 39.18 | 42.59 | 35.55 |
Columns are period end dates · fundamentals updated 2 Oct 2026